Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 12/2020

01-12-2020 | Coronary Heart Disease | Coronary Heart Disease (S Virani and S Naderi, Section Editors)

The Role of the Gut Microbiota in Coronary Heart Disease

Authors: Huagang Liu, Junli Zhuang, Peng Tang, Jie Li, Xiaoxing Xiong, Hongping Deng

Published in: Current Atherosclerosis Reports | Issue 12/2020

Login to get access

Abstract

Purpose of Review

This review focuses on recent evidence examining the role gut microbiota play in coronary heart disease. It also provides a succinct overview of current and future therapies targeting the gut microbiota for coronary heart disease risk reduction.

Recent Findings

A consensus has been reached that differences exist in the gut microbiotas of patients with coronary heart disease. Studies have shown that the gut microbiota is associated with obesity, diabetes, dyslipidemia, and hypertension, which are risk factors for coronary heart disease. The gut microbiota is involved in mediating basic metabolic processes, such as cholesterol metabolism, uric acid metabolism, oxidative stress, and inflammatory reactions, through its metabolites, which can induce the development of atherosclerosis and coronary heart disease. Interfering with the composition of gut microbiota, supplementing probiotics, and fecal donation are active areas of research to potentially prevent and treat coronary heart disease.

Summary

Gut microbiota are causally associated with coronary heart disease. We analyzed the gut microbiota’s effects on risk factors for coronary heart disease and studied the effects of gut microbiota metabolites on coronary heart disease. Gut microbiota is a potential target for preventing and treating coronary heart disease.
Literature
1.
Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121–41.
2.
Qin J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65.
3.
Li J, et al. An integrated catalog of reference genes in the human gut microbiome. Nat Biotechnol. 2014;32(8):834–41.
4.
Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334(6052):105–8.
5.
Milani C, Ferrario C, Turroni F, Duranti S, Mangifesta M, van Sinderen D, et al. The human gut microbiota and its interactive connections to diet. J Hum Nutr Diet. 2016;29(5):539–46.
6.
• Sommer F, et al. The resilience of the intestinal microbiota influences health and disease. Nat Rev Microbiol. 2017;15(10):630 The composition of the intestinal microbiota varies among individuals and throughout development, and is dependent on host and environmental factors. However, although the microbiota is constantly exposed to environmental challenges, its composition and function in an individual are stable against perturbations, as microbial communities are resilient and resistant to change.
7.
Zhuang X, Xiong L, Li L, Li M, Chen M. Alterations of gut microbiota in patients with irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2017;32(1):28–38.
8.
Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635–8.
9.
• Wang Z, et al. Gut flora metabolism of phosphatidylcholine promotescardiovascular disease. Nature. 2011;472(7341):57–63 Studies using germ-free mice confirmed a critical role for dietary choline and gut flora in TMAO production, augmented macrophage cholesterol accumulation and foam cell formation.
10.
Korem T, Zeevi D, Suez J, Weinberger A, Avnit-Sagi T, Pompan-Lotan M, et al. Growth dynamics of gut microbiota in health and disease inferred from single metagenomic samples. Science. 2015;349(6252):1101–6.
11.
Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017;5(1):14.
12.
•• Senthong V, et al. Intestinal microbiota-Generated metabolite Trimethylamine-N-Oxide and 5-Year mortality risk in stable coronary artery disease: the contributory role of intestinal microbiota in aCOURAGE-Like patient cohort. Journal of the American Heart Association, 2016;5(6):e002816. This study examined the clinical prognostic value of TMAO in patients with stable coronary artery disease. The results showed that elevated plasma TMAO levels portended higher long-term mortality risk among patients with stable coronary artery disease managed with optimal medical treatment.
13.
•• Santisteban MM, et al. Hypertension-linked pathophysiological alterations in the gut. Circ Res. 2016;120(2):312 Gut epithelial integrity and wall pathology were examined in spontaneously hypertensive rat and chronic angiotensin II infusion rat models. The results showed that a dysfunctional sympathetic-gut communication is associated with gut pathology, dysbiosis, and inflammation and plays a key role in hypertension???
14.
• Backhed F, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718–23 The gut microbial community (microbiota) is essential for processing dietary polysaccharides. We found that conventionalization of adult germ-free (GF) C57BL/6 mice with a normal microbiota harvested from the distal intestine (cecum) of conventionally raised animals produces a 60% increase in body fat content and insulin resistance within 14 days despite reduced food intake. The gut microbiota is an important environmental factor that affects energy harvest from the diet and energy storage in the host.
15.
Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–31.
16.
Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022–3.
17.
den Besten G, Lange K, Havinga R, van Dijk TH, Gerding A, van Eunen K, et al. Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids. Am J Physiol Gastrointest Liver Physiol. 2013;305(12):G900–10.
18.
Flint HJ, Scott KP, Duncan SH, Louis P, Forano E. Microbial degradation of complex carbohydrates in the gut. Gut Microbes. 2012;3(4):289–306.
19.
• Geurts L, et al. Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: impact on apelin regulation in adipose tissue. Front Microbiol. 2011;2:149 This study have investigated gut microbiota composition in obese and diabetic leptin-resistant mice (db/db) by combining pyrosequencing and phylogenetic microarray analysis of 16S ribosomal RNA gene sequences. It identified the roles of the eCB and LPS in the regulation of apelinergic system tone (apelin and APJ mRNA expression) in genetic obese and diabetic mice. By using in vivo and in vitro models, It have demonstrated that both the eCB and low-grade inflammation differentially regulate apelin and APJ mRNA expression in adipose tissue.
20.
Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes. 2012;3(4):279–88.
21.
Muccioli GG, Naslain D, Bäckhed F, Reigstad CS, Lambert DM, Delzenne NM, et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol. 2010;6:392.
22.
• Haffner SM. Coronary heart disease in patients with diabetes. N Engl J Med. 2000;342(14):1040–2 Diabetes is a major risk factor for coronary heart disease.
23.
Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. BMJ. 2011;343:d7163.
24.
• Qin J, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60 To carry out analysis on gut microbial content in patients with type 2 diabetes, we developed a protocol for a metagenome-wide association study (MGWAS) and undertook a two-stage MGWAS based on deep shotgun sequencing of the gut microbial DNA from 345 Chinese individuals. MGWAS analysis showed that patients with type 2 diabetes were characterized by a moderate degree of gut microbial dysbiosis, a decrease in the abundance of some universal butyrate-producing bacteria and an increase in various opportunistic pathogens, as well as an enrichment of other microbial functions conferring sulphate reduction and oxidative stress resistance.
25.
Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99–103.
26.
Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, Jensen BAH, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature. 2016;535(7612):376–81.
27.
• Cani PD, et al. Changes in gut microbiota control metabolic endotoxemiainduced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470–81 It found that changes of gut microbiota induced by an antibiotic treatment reduced metabolic endotoxemia and the cecal content of LPS in both high-fat-fed and ob/ob mice. These changes are involved in insulin resistance-induced obesity by regulating TLR4.
28.
Amyot J, Semache M, Ferdaoussi M, Fontés G, Poitout V. Lipopolysaccharides impair insulin gene expression in isolated islets of Langerhans via Toll-like receptor-4 and NF-kappaB signalling. PLoS One. 2012;7(4):e36200.
29.
Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61(2):364–71.
30.
Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116(11):3015–25.
31.
•• Wang TJ, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448–53 Emerging technologies allow the high-throughput profiling of metabolic status from a blood specimen (metabolomics). Five branched-chain and aromatic amino acids had highly significant associations with future diabetes: isoleucine, leucine, valine, tyrosine and phenylalanine. Those short-chain fatty acids binding to G-protein-coupled receptor 41/43 can also affect anti-inflammatory and brain-gut peptide hormone secretion functions, resulting in insulin resistance and islet cell dysfunction.
32.
El-Mesallamy HO, et al. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism. 2011;60(1):63–70.
33.
Delzenne NM, Cani PD. Nutritional modulation of gut microbiota in the context of obesity and insulin resistance: potential interest of prebiotics. Int Dairy J. 2010;20(4):277–80.
34.
Perino A, Pols TWH, Nomura M, Stein S, Pellicciari R, Schoonjans K. TGR5 reduces macrophage migration through mTOR-induced C/EBPbeta differential translation. J Clin Invest. 2014;124(12):5424–36.
35.
•• Fang S, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med. 2015;21(2):159–65 Bile acid release during a meal selectively activates intestinal farnesoid X receptor (FXR). By mimicking this tissue-selective effect, the gut-restricted FXR agonist fexaramine (Fex) robustly induces enteric fibroblast growth factor 15 (FGF15), leading to alterations in BA composition, but does so without activating FXR target genes in the liver. These pronounced metabolic improvements suggest tissue-restricted FXR activation as a new approach in the treatment of obesity and metabolic syndrome.
36.
Fu J, Bonder MJ, Cenit MC, Tigchelaar EF, Maatman A, Dekens JAM, et al. The gut microbiome contributes to a substantial proportion of the variation in blood lipids. Circ Res. 2015;117(9):817–24.
37.
• Wang Z, et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J. 2014;35(14):904–10 It examined the relationship between fasting plasma choline and betaine levels and risk of major adverse cardiac events (MACE = death, myocardial infraction, stroke) in relation to TMAO over 3 years of follow-up in 3903 sequential stable subjects undergoing elective diagnostic coronary angiography. The results show that elevated plasma levels of choline and betaine are each associated with incident MACE risk independent of traditional risk factors. However, high choline and betaine levels are only associated with higher risk of future MACE with concomitant increase in TMAO.
38.
Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A, Karns R, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014;509(7499):183–8.
39.
Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10(3):167–77.
40.
• Tang, W.H., et al., Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med, 2013. 368(17): p. 1575–1584. It investigated the relationship among intestinal microbiota-dependent metabolism of dietary phosphatidylcholine, TMAO levels, and adverse cardiovascular events in humans. The results show that TMAO can cause blood lipid abnormalities and atheromatous plaques by affecting cholesterol transport and metabolism and bile acid levels. Increased TMAO levels are associated with an increased risk of incident major adverse cardiovascular events.
41.
Warrier M, et al. The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance. In: Cell Rep; 2015.
42.
• Nakamura Y, et al. Effect of fermented bean paste on serum lipids in rats fed a cholesterol-free diet. Biosci Biotechnol Biochem. 2009;73(11):2506–12 It suggest that dysbacteria can cause SCFA secretion insufficiency and dyslipidemia.
43.
Pereira DIA, Mccartney AL, Gibson GR. An in vitro study of the probiotic potential of a bile-salt-hydrolyzing Lactobacillus fermentum strain, and determination of its cholesterol-lowering properties. Appl Environ Microbiol. 2003;69(8):4743–52.
44.
Larkin TA, Astheimer LB, Price WE. Dietary combination of soy with a probiotic or prebiotic food significantly reduces total and LDL cholesterol in mildly hypercholesterolaemic subjects. Eur J Clin Nutr. 2009;63(2):238–45.
45.
Li C, Li X, Han H, Cui H, Peng M, Wang G, et al. Effect of probiotics on metabolic profiles in type 2 diabetes mellitus: a meta-analysis of randomized, controlled trials. Medicine (Baltimore). 2016;95(26):e4088.
46.
• Tao Y, et al. Gut dysbiosis is linked to hypertension. Hypertension. 2015;65(6):1331–40 It demonstrate that high blood pressure is associated with gut microbiota dysbiosis, both in animal and human hypertension. Analysis of the fecal bacteria from rats with primary hypertension revealed significantly decreased bacterial numbers and diversity. The proportions of thick-walled bacteria and Bacteroides increased, and SCFA production decreased.
47.
Pluznick J. A novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microbes. 2014;5(2):202–7.
48.
•• Richards EM, et al. The gut, its microbiome, and hypertension. Curr Hypertens Rep. 2017;19(4):36 Animal models of HTN have shown that gut pathology occurs in hypertension. SCFAs play roles in maintaining intestinal epithelial barrier functions. They can reduce inflammatory reactions, directly affect immune cells, and reduce sympathetic activity to improve hypertension.
49.
• Afsar B, et al. Gut hormones and gut microbiota: implications for kidney function and hypertension. J Am Soc Hypertens. 2016;10(12):954–61 Alterations in the structure and function of the gut microbiota have been shown to play a key role in the pathogenesis and complications of numerous diseases including hypertension. Gut microbiota can affect the formation of vasoactive hormones, such as serotonin, dopamine and norepinephrine, thus playing a role in regulating blood pressure.
50.
Khalesi S, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension. 2014;64(4):897–903.
51.
Chen Y, Liu W, Xue J, Yang J, Chen X, Shao Y, et al. Angiotensin-converting enzyme inhibitory activity of Lactobacillus helveticus strains from traditional fermented dairy foods and antihypertensive effect of fermented milk of strain H9. J Dairy Sci. 2014;97(11):6680–92.
52.
•• Yissachar N, et al. An intestinal organ culture system uncovers a role for the nervous system in microbe-immune crosstalk. Cell. 2017;168(6):1135–1148.e12 Host-environment interactions in the gut partake in bifurcating proor anti-inflammatory responses to microbes, which can lead to the development of atherosclerosis and coronary heart disease.
53.
• Jandhyala SM, et al. Role of the normal gut microbiota. World J Gastroenterol. 2015;21(29):8787–803 This paper reviews the role of the gut microbiota in normal metabolism and discusses the effect of abnormal metabolism on atherosclerosis.
54.
• Karlsson FH, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 2012;3:1245 This study use shotgun sequencing of the gut metagenome to demonstrate that the genus Collinsella was enriched in patients with symptomatic atherosclerosis, defined as stenotic atherosclerotic plaques in the carotid artery leading to cerebrovascular events, whereas Roseburia and Eubacterium were enriched in healthy controls.
55.
Emoto T, Yamashita T, Kobayashi T, Sasaki N, Hirota Y, Hayashi T, et al. Characterization of gut microbiota profiles in coronary artery disease patients using data mining analysis of terminal restriction fragment length polymorphism: gut microbiota could be a diagnostic marker of coronary artery disease. Heart Vessel. 2017;32(1):39–46.
56.
Emoto T, Yamashita T, Sasaki N, Hirota Y, Hayashi T, So A, et al. Analysis of gut microbiota in coronary artery disease patients: a possible link between gut microbiota and coronary artery disease. J Atheroscler Thromb. 2016;23(8):908–21.
57.
Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–85.
58.
Craciun S, Balskus EP. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc Natl Acad Sci U S A. 2012;109(52):21307–12.
59.
Koeth RA, Levison BS, Culley MK, Buffa JA, Wang Z, Gregory JC, et al. Gamma-butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab. 2014;20(5):799–812.
60.
•• Wang Z, et al. Non-lethal inhibition of gut microbial Trimethylamine production for the treatment of atherosclerosis. Cell. 2015;163(7):1585–95 Trimethylamine (TMA) N-oxide (TMAO), a gut-microbiota-dependent metabolite, both enhances atherosclerosis in animal models and is associated with cardiovascular risks in clinical studies.
61.
• CM O, K R. Heartbeat: the gut microbiota and heart failure. Heart. 2016;102(11):811 TMAO increases the risk of cardiovascular disease.
62.
Tang WH, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575–84.
63.
Brugere JF, et al. Archaebiotics: proposed therapeutic use of archaea to prevent trimethylaminuria and cardiovascular disease. Gut Microbes. 2014;5(1):5–10.
64.
• Zhu W, et al. Gut microbial metabolite TMAO enhances platelet Hyperreactivity and thrombosis risk. Cell. 2016;165(1):111–24 Gut microbes, through generation of trimethylamine N-oxide (TMAO), directly contribute to platelet hyperreactivity and enhanced thrombosis potential.
65.
•• Seldin MM, et al. Trimethylamine N-oxide promotes vascular inflammation through Signaling of mitogen-activated protein kinase and nuclear factor-κB. J Am Heart Assoc. 2016;5(2):e002767 The impact of TMAO on endothelial and smooth muscle cell function in vivo, focusing on disease-relevant outcomes for atherogenesis. TMAO can rapidly send signals to cells within minutes. In endothelial or smooth muscle cells, TMAO can quickly induce activation of mitogen-activated protein kinase and NF-κB and cause upregulation of downstream adhesion molecules???The results suggest a likely contributory mechanism for TMAO-dependent enhancement in atherosclerosis and cardiovascular risks.
66.
• Tang WHW, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116(3):448–55 Elevated TMAO levels were associated with corresponding increases in tubulointerstitital fibrosis and collagen deposition and phosphorylation of Smad3.
67.
Brown JM, Hazen SL. Microbial modulation of cardiovascular disease. Nat Rev Microbiol. 2018;16(3):171–81.
68.
• Wang L, Qu LI. Imbalance of fecal microbiota in patients with coronary heart disease is correlated with uric acid metabolism. Modern Digestion & Intervention; 2012. Elevated serum uric acid levels increase oxygen free radical production, induce oxidative stress and induce endothelial dysfunction. These changes induce and aggravate the occurrence of atherosclerosis.
69.
Ruggiero C, Cherubini A, Guralnik J, Semba RD, Maggio M, Ling SM, et al. The interplay between uric acid and antioxidants in relation to physical function in older persons. J Am Geriatr Soc. 2007 Aug;55(8):1206–15.
70.
•• Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–74 Atherosclerosis is an inflammatory disease within the arterial wall that is responsible for several important adverse vascular events, including coronary artery disease, myocardial infraction, stroke and peripheral artery disease.
71.
Koren O, Spor A, Felin J, Fak F, Stombaugh J, Tremaroli V, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4592–8.
72.
Nadhazi Z, et al. Plasma endotoxin level in healthy blood donors. Orv Hetil. 1998;139(48):2889–91.
73.
Seth RN, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118(2):229–41.
74.
•• Cani PD, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–72 Diabetes and obesity are two metabolic diseases characterized by insulin resistance and a low-grade inflammation. It conclude that the LPS/CD14 system sets the tone of insulin sensitivity and the onset of diabetes and obesity.
75.
Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007;50(11):2374–83.
76.
Mangge H, Almer G, Truschnig-Wilders M, Schmidt A, Gasser R, Fuchs D. Inflammation, adiponectin, obesity and cardiovascular risk. Curr Med Chem. 2010;17(36):4511–20.
77.
Lam V, Su J, Koprowski S, Hsu A, Tweddell JS, Rafiee P, et al. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J. 2012;26(4):1727–35.
78.
•• Lam V, et al. Intestinal microbial metabolites are linked to severity of myocardial infarction in rats. PLoS One. 2016;11(8):e0160840 This study links gut microbiota metabolites to severity of myocardial infarction and may provide future opportunities for novel diagnostic tests. Antibiotic-induced changes in the abundance of individual groups of intestinal microbiota dramatically altered the host's metabolism and interventions for the prevention of cardiovascular disease.
79.
• Gan XT, et al. Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circ Heart Fail. 2014;7(3):491–9 Probiotics are extensively used to promote gastrointestinal health, and emerging evidence suggests that their beneficial properties can extend beyond the local environment of the gut. The study suggests that probiotics offer promise as a potential therapy for the attenuation of heart failure.
80.
•• Almoosawi S, et al. Daily profiles of energy and nutrient intakes: are eating profiles changing over time? Eur J Clin Nutr. 2012;66(6):678–86 Associations between timing of eating occasions and their nutrient composition and health have been described in interventional and cross-sectional studies.prebiotics andprobiotics are the main therapeutic tools for regulating gut microbiota imbalances.
81.
Broekaert WF, Courtin CM, Verbeke K, van de Wiele T, Verstraete W, Delcour JA. Prebiotic and other health-related effects of cereal-derived arabinoxylans, arabinoxylan-oligosaccharides, and xylooligosaccharides. Crit Rev Food Sci Nutr. 2011;51(2):178–94.
82.
Vrieze A, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913–6.e7.
Metadata
Title
The Role of the Gut Microbiota in Coronary Heart Disease
Authors
Huagang Liu
Junli Zhuang
Peng Tang
Jie Li
Xiaoxing Xiong
Hongping Deng
Publication date
01-12-2020
Publisher
Springer US
Published in
Current Atherosclerosis Reports / Issue 12/2020
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-020-00892-2

Other articles of this Issue 12/2020

Current Atherosclerosis Reports 12/2020 Go to the issue

Coronary Heart Disease (S Virani and S Naderi, Section Editors)

Intra-coronary Imaging for the Evaluation of Plaque Modifications Induced by Drug Therapies for Secondary Prevention

Women and Ischemic Heart Disease (P. Kohli , Section Editor)

State of the Art in Noninvasive Imaging of Ischemic Heart Disease and Coronary Microvascular Dysfunction in Women: Indications, Performance, and Limitations

Vascular Biology (J Hamilton, Section Editor)

Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications

Coronary Heart Disease (S. Virani and S. Naderi, Section Editor)

Digital Health Innovations to Improve Cardiovascular Disease Care

Reviews and New Research Implications (S.Virani, Section Editor)

Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well

Nonstatin Drugs (M. Vrablik, Section Editor)

Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits